SMMT
Summit Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$13.50-2.24%
Price as of Jul 20, 2026
SMMT growth
Summit Therapeutics Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -79.7%
- Operating cash flow
- -80.0%
Forward estimates
- Revenue
- —
- EBITDA
- +101.1%
- EPS
- +0.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.